In the span of about nine months, the research peptide market lost its largest vendor, watched federal agents physically raid a warehouse for the first time, and saw a compounding pharmacy forfeit nearly $2 million in a criminal case that’s now cited as the template for how these prosecutions get built. If you’ve ordered from this space at any point in the last few years, there’s a real chance you’ve bought from a company that no longer exists, run by people who are now under federal supervision instead of running a business.
Here’s the timeline, in order, and what each closure actually tells you about how this market is being dismantled from three directions at once: physical enforcement, criminal prosecution, and voluntary collapse under pressure nobody could survive.
June 2025: The First Physical Raid
Before 2025, FDA enforcement against peptide vendors mostly meant warning letters — a formal notice, a deadline to comply, and in a lot of cases, nothing that actually changed how a business operated. In June 2025, that changed. FDA agents physically raided Amino Asylum’s warehouse, seizing inventory and halting operations overnight. It was reported at the time as the first physical raid the agency had carried out against a major peptide vendor, rather than a paper warning that a company could quietly ignore.
The significance wasn’t the size of the company. It was the method. A raid means agents had enough evidence to act immediately rather than build a civil case over months. For an industry that had, up to that point, mostly treated warning letters as a cost of doing business, a warehouse raid was a different kind of message entirely.
March 6, 2026: The Largest Vendor in the Country Shuts Down Overnight
Peptide Sciences was, by most industry accounts, the largest research peptide vendor operating in the United States. On March 6, 2026, it posted a brief notice confirming a voluntary shutdown and immediately stopped processing orders. No detailed explanation. No stated refund process for customers with orders in flight. The company that had spent years building itself into the default option for researchers simply stopped.
The reasons, pieced together from industry reporting rather than a single company statement, appear to be converging rather than singular. Increasing FDA and DOJ enforcement activity through 2024 and 2025 raised the cost and risk of staying in business. New legislation introduced in early 2026 aimed at explicitly banning research-chemical sales of compounds biologically identical to already-approved drugs threatened the core of the business model. And independent third-party testing — specifically from Janoshik Analytical, a lab researchers widely use to spot-check vendor claims — had returned failing grades across parts of the Peptide Sciences catalog, including an “E” rating on CJC-1295, an “E” on Tesamorelin, and an “E” on Retatrutide across 37 samples tested.
Put plainly: the market’s biggest, most established name was being outed by independent lab testing at the same time regulatory pressure was peaking, and it chose to close rather than fight both battles in public. Customers with pending orders were, by most accounts, left with no refund and no explanation.
The Precedent Case: Tailor Made Compounding
Years before this wave of closures, one case set the legal template prosecutors are still using. Tailor Made Compounding LLC, a compounding pharmacy, pleaded guilty to distributing BPC-157 and other unapproved peptides and was forced to forfeit $1.79 million. The company’s CEO pleaded guilty personally to related federal charges. The FDA had already sent the pharmacy a letter demanding it stop compounding certain peptides by April 23, 2020, and prohibited further sales by May 15, 2020 — deadlines the company reportedly did not fully observe.
The legal reasoning is worth understanding because it applies to essentially every “research use only” peptide sold today. Under Section 503A of the Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may only compound a substance if it’s supported by a recognized pharmacopeia monograph, is a component of an already-FDA-approved drug, or appears on the FDA’s approved bulk substances list. BPC-157 met none of those conditions. That’s not a labeling technicality — it’s the exact legal gap that makes compounded BPC-157, and a long list of other peptides in the same regulatory position, illegal to dispense for human use regardless of how a pharmacy or vendor markets it.
Three Different Ways to Disappear
What makes this run of closures worth studying together, rather than as isolated news items, is that each one represents a different failure mode — and together they cover almost every way a peptide business can end.
Amino Asylum ended by physical raid: the government had enough to act immediately, no warning, no wind-down period.
Tailor Made Compounding ended by criminal prosecution: years of buildup from an initial warning letter to a guilty plea and a seven-figure forfeiture, with the CEO personally on the hook.
Peptide Sciences ended by voluntary collapse: no raid, no indictment on the public record, just a company that saw the combination of regulatory pressure, pending legislation, and its own products failing independent lab testing, and chose to close rather than keep operating.
Notice what’s missing from all three: an orderly wind-down that protected customers. In every case, people with money already spent and orders already placed were left with nothing when the business disappeared. That’s the risk that never shows up on a vendor’s homepage, and it’s structurally different from “did I get a good product this time.” It’s “does this company still exist in six months if something goes wrong with my order.”
What To Actually Do With This
None of this means every peptide vendor is on the same trajectory. It does mean that a vendor’s size, longevity, and polish are not reliable predictors of stability — Peptide Sciences was the largest name in the space and still folded overnight. The more useful signals are the ones we walk through in our Vendor Guide: independently verifiable Certificates of Analysis with real batch numbers and a named, checkable testing lab, transparent sourcing claims, and a track record that holds up under scrutiny from third-party testing services rather than just customer reviews.
We’re tracking the broader enforcement pattern, including the federal case that sent a peptide vendor’s owner to prison, in our Grey Market Watch hub.
This article summarizes publicly reported enforcement actions and company closures. It is not legal advice and does not encourage the purchase or use of unapproved drugs for human consumption.